AI assistant
DEXCOM INC — Director's Dealing 2014
Nov 26, 2014
30198_dirs_2014-11-26_02fd6d41-f97e-4dfe-9ef2-e17ea574b051.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2014-11-24
Reporting Person: DOUBLEDAY RICHARD (Sr. VP. Worldwide Sales)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-11-24 | Common Stock | M | 4000.0 | $6.03 | Acquired | 123950 | Direct |
| 2014-11-24 | Common Stock | S | 4000.0 | $50.3616 | Disposed | 119950 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-11-24 | Non-Qualified Stock Option (right to buy) | $6.03 | M | 4000.0 | Disposed | 2019-06-22 | Common Stock (4000) | Direct |
Footnotes
F1: On March 10, 2014, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $50.15 to $50.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 89,271 unvested restricted stock units, 50,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017, 10,000 of which were granted on May 31, 2013 and shall vest through May 31, 2016, 25,000 of which were granted on March 11, 2013 and shall vest through March 11, 2016, and 4,271 of which were granted on March 8, 2012 and shall vest through March 8, 2015.